Low-profile eye drop developer spells out the game plan that drew Brent Saunders to the board — and it involves going earlier than anti-VEGFs

OcuTerra is stepping into the limelight with the final close of a $35 million Series B, which is designed to fund a Phase II trial of its lead eye drop and thereby nail down proof of concept for what it calls a non-invasive option for a sizable swath of patients at the early stages of diabetic retinal disease and wet age-related macular degeneration.